COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,363 Articles (22,803 medRxiv, 8,560 bioRxiv)

Most recent first Previous |  Page 1042: Articles 10411-10420  | Next

Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study.
Gray, G. E., COLLIE, S., Garrett, N., Goga, A., Champion, J., Zylstra, M., Reddy, T., Yende, N., Seocharan, I., Takalani, A., Sanne, I., Mayat, F., Odhiambo, J., Bamford, L., Moultrie, H., Fairall, L., Bekker, L.-G.
10.1101/2021.12.28.21268436 — Posted: 2021-12-29 Discussion: Onsite
Dynamic Expedition of Leading Mutations in SARS-CoV-2 Spike Glycoproteins
He, Z., Hasan, M., Jia, M., Natarajan, K., Yap, S. Q., Zhou, F., Su, H., Zhu, K., Su, H.
10.1101/2021.12.29.474427 — Posted: 2021-12-29
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529
Wang, Q., Anang, S., Iketani, S., Guo, Y., Liu, L., Ho, D. D., Sodroski, J. G.
10.1101/2021.12.27.474288 — Posted: 2021-12-29
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, T. L., Ying, B., Whitener, B., VanBlargan, L., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A., Halfmann, P., Kawaoka, Y., Elbashir, S., Edwards, D. K., Thackray, L., Diamond, M., Boon, A.
10.1101/2021.12.29.474432 — Posted: 2021-12-29
A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine
Chakraborty, K., Chandrashekar, A., Sidaway, A., Latta, E., Yu, J., McMahan, K., Manickam, C., Kroll, K., Mosher, M., Reeves, R. K., Gam, R., Arthofer, E., Choudhry, M., Barouch, D. H., Henley, T.
10.1101/2021.12.28.474336 — Posted: 2021-12-29
In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease in the absence of dexamethasone-treatable vaccine-associated enhanced respiratory pathology
Ebenig, A., Muraleedharan, S., Kazmierski, J., Todt, D., Auste, A., Anzaghe, M., Gömer, A., Postmus, D., Gogesch, P., Niles, M., Plesker, R., Miskey, C., Gellhorn Serra, M., Breithaupt, A., Hörner, C., Kruip, C., Ehmann, R., Ivics, Z., Waibler, Z., Pfaender, S., Wyler, E., Landthaler, M., Kupke, A., Nouailles, G., GOFFINET, C., Brown, R. J. P., Mühlebach, M. D.
10.1101/2021.12.28.474359 — Posted: 2021-12-28
Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
Yin, W., Xu, Y., Xu, P., Cao, X., Wu, C., Gu, C., He, X., Wang, X., Huang, S., Yuan, Q., Wu, K., Hu, W., Huang, Z., Liu, J., Wang, Z., Jia, F., Xia, K., Liu, P., Wang, X., Song, B., Zheng, J., Jiang, H., Cheng, X., Jiang, Y., Deng, S.-J., Xu, H. E.
10.1101/2021.12.27.474273 — Posted: 2021-12-28
Peptide-based epitope design on non-structural proteins of SARS-CoV-2
RS, S., S, V., E, B. S., Elumalai, E., Gupta, K. K.
10.1101/2021.12.27.474315 — Posted: 2021-12-28
Mapping the allosteric effects that define functional activity of SARS-CoV-2 specific antibodies
Tulsian, N. K., Raghuvamsi, P. V., Qian, X., Yue, G., D/O Shunmuganathan, B., Samsudin, F., Wong, Y. H., Jianqing, L., Purushotorman, K., McQueen, M. K., Wang, B., Lescar, J., Wang, C.-I., Anand, G., Bond, P. J., MacAry, P. A.
10.1101/2021.12.27.474251 — Posted: 2021-12-28
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Vangeel, L., De Jonghe, S., Maes, P., Slechten, B., Raymenants, J., Andre, E., Neyts, J., Jochmans, D.
10.1101/2021.12.27.474275 — Posted: 2021-12-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).